Stimulating the differentiation of predipocytic cells and therapies based thereon

• US 5,827,897 A
• Filed: 01/22/1997
• Issued: 10/27/1998
• Est. Priority Date: 08/02/1994
• Status: Expired due to Term

• Current Assignee: Galderma Research And Development Snc (Nestle SA)
• Original Assignee: Centre International de Recherches Dermatologiques Galderma
• Inventors: Ailhaud, Gerald, Reichert, Uwe, Safonova, Irina, Shroot, Braham, Grimaldi, Paul
• Primary Examiner(s): Weddington, Kevin E.
• Application Number:
  US08/787,216
• Time in Patent Office: 643 Days
• Field of Search: 514/725, 514/557, 514/558, 514/560, 514/549, 514/530
• US Class Current: 514/725
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/20 having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

The differentiation of preadipocytic cells into adipocytic cells, in particular for correcting insulin-resistance disease states in mammalian organisms, notably in humans, for example type II diabetes and cardiovascular disorders such as hypertension and atherosclerosis, is stimulated by treating such preadipocytic cells, or a patient in need of such treatment, with an effective amount of (a) at least one ligand displaying affinity for the nuclear receptors for retinoic acid and/or isomers thereof, preferably at least one ligand displaying a specific affinity for the RAR receptors and even more preferably the RAR-α receptor and (b) at least one fatty acid, e.g., a polyunsaturated fatty acid.

Claims

1. A regimen for treating an insulin-resistant state in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of (a) at least one ligand displaying affinity for the nuclear receptors for retinoic acid and/or isomers thereof, and (b) at least one fatty acid.

2. The regimen as defined by claim 1, for the treatment of type II diabetes.

3. A The regimen as defined by claim 1, for the treatment of a cardiovascular disease state.

4. The regimen as defined by claim 1, comprising simultaneously administering said at least one ligand (a) and said at least one fatty acid (b).

5. The regimen as defined by claim 1, comprising separately administering said at least one ligand (a) and said at least one fatty acid (b).

6. The regimen as defined by claim 1, comprising staggeredly administering said at least one ligand (a) and said at least one fatty acid, over time.

8. The regimen of claim 1, said at least one ligand (a) comprising a ligand displaying a selective affinity for the RAR receptors.

9. The regimen as defined by claim 8, said at least one RAR-specific ligand (a) not displaying selective affinity for one of the subtypes of RAR receptors.

10. The regimen as defined by claim 8, said at least one ligand (a) displaying a selective affinity for the RAR receptors also displaying a selective affinity for at least one of the subtypes of RAR receptors.

11. The regimen as defined by claim 8, said at least one of the subtypes of RAR receptors comprising the RAR-α

receptor.

12. The regimen as defined by claim 1, said at least one ligand (a) being selected from the group consisting of 4- (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carboxamido!benzoic acid, 4- (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl!benzoic acid, all-trans-retinoic acid, 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)benzoic acid, 4- (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carboxamido!benzoic acid, 6- 3-(1-adamantyl)-4-hydroxyphenyl!-2-naphthoic acid, 6- 3-(1-methylcyclohexyl)-4-methoxyphenyl!-2-naphthoic acid and adapalene.

13. The regimen as defined by claim 1, said at least one fatty acid (b) comprising a saturated or unsaturated fatty acid.

14. The regimen as defined by claim 13, said at least one fatty acid (b) comprising a polyunsaturated fatty acid.

15. The regimen as defined by claim 14, said polyunsaturated fatty acid having from 18 to 22 carbon atoms.

16. The regimen as defined by claims 14, said polyunsaturated fatty acid being of W₃ or W₆ type.

17. The regimen as defined by claim 1, said at least one fatty acid (b) being selected from the group consisting of arachidonic acid, dihomo-gamma-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, oleic acid, linoleic acid, α

-linolenic acid, γ

-linolenic acid, palmitic acid and α

-bromopalmitic acid.

7. A regimen for treating an insulin-resistant state in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of a composition of matter suited for the differentiation of preadipocytic cells into adipocytic cells comprising (a) at least one ligand displaying affinity for the nuclear receptors for retinoic acid and/or isomers thereof, and (b) at least one fatty acid.

18. The regimen as defined by claim 7, wherein said at last one ligand (a) is selected from the group consisting of 4- (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carboxamido!benzoic acid, 4- (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl!benzoic acid, all-trans-retinoic acid, 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)benzoic acid, 4- (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carboxamido!benzoic acid, 6- 3-(1-adamantyl)-4-hydroxyphenyl!-2-naphthoic acid, 6- 3-(1-methylcyclohexyl)-4-methoxyphenyl!-2-naphthoic acid and adapalene.

19. The regimen as defined by claim 7, wherein said at least one fatty acid (b) comprises a saturated or unsaturated fatty acid.

20. The regimen as defined by claim 19, said at least one fatty acid (b) comprising a polyunsaturated fatty acid.

21. The regimen as defined by claim 20, said polyunsaturated fatty acid having from 18 to 22 carbon atoms.

22. The regimen as defined by claim 20, said polyunsaturated fatty acid being of W₃ or W₆ type.

23. The regimen as defined by claims 7, said at least one fatty acid (b) being selected from the group consisting of arachidonic acid, dihomo-gamma-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, oleic acid, linoleic acid, α

-linolenic acid, γ

-linolenic acid, palmitic acid or a-bromopalmitic acid.